文献速递流行病学与生物统计基础与转化研究

英格兰和威尔士将13价肺炎球菌结合疫苗方案从2+1改为1+1的预估影响:一项建模研究

Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
PubMed 文献 · PLoS Med · 2019-07-03

该建模研究评估英格兰和威尔士将PCV13方案从2+1改为1+1对侵袭性肺炎球菌疾病(IPD)和肺炎球菌社区获得性肺炎(CAP)的影响。结果显示,改为1+1方案总体影响很小,疫苗型IPD的小幅增加被非疫苗型IPD的减少所抵消。2018年改为1+1方案预测5年内增加31例IPD和83例肺炎球菌CAP,合计增加8例死亡,15岁以下儿童无死亡。

要点

  • 在当前PCV规划成熟状态下,减少一剂基础免疫对IPD和肺炎球菌CAP影响很小。
  • 1+1方案可提高规划效率,并便于引入新疫苗。
  • 研究结果不适用于肺炎球菌流行病学不同或规划不成熟、群体免疫差的其他地区。

核心结论

  • 在英格兰和威尔士PCV规划成熟状态下,将2+1方案改为1+1方案对IPD、肺炎球菌CAP及相关死亡总体影响很小。

研究设计与样本

  • 研究构建了英格兰和威尔士的年龄结构、动态、确定性肺炎球菌传播模型,拟合2001/2002年携带数据和至2015年的接种后IPD数据。
  • 从大参数空间中筛选出500个似然统计上接近最大值的参数集用于预测未来病例。

主要发现

  • 2014年以来非PCV13(非疫苗血清型[NVT])IPD病例快速增加可能由持续替换中出现的个别高毒力NVT导致,预测NVT增加将从2020年起趋于平稳。
  • 长期模拟提示改为1+1方案总体影响很小,疫苗型IPD的小幅增加被NVT IPD的减少所抵消。
  • 基础情景下,2018年改为1+1方案预测5年内增加31例(6,76)IPD病例和83例(-10,242)肺炎球菌CAP病例,合计增加8例(-2,24)死亡,15岁以下儿童无死亡。
  • 长期维持2+1或改为1+1均预测可维持64岁以下人群IPD病例的当前下降,但65岁及以上人群病例将因人口老龄化持续增加。

临床怎么用

  • 研究结果支持在英格兰和威尔士当前PCV规划成熟背景下,减少一剂基础免疫以改善规划效率并便于引入新疫苗。
  • 研究结果不应适用于肺炎球菌流行病学不同或规划不成熟、群体免疫差的其他地区。

局限性

  • 模型难以拟合某些年龄组NVT IPD的既往趋势。
  • 对未来NVT行为存在固有不确定性。
  • 定义65岁及以上人群混合矩阵的数据稀疏。
  • 预测不确定性的定义存在方法学挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In October 2017, the United Kingdom Joint Committee on Vaccination and Immunisation (JCVI) recommended removal of one primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing 2+1 schedule (2, 4, 12 months). We conducted a mathematical modelling study to investigate the potential impact of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP). Our results and those from a 1+1 immunogenicity study formed the key evidence reviewed by JCVI. METHODS AND FINDINGS: We developed age-structured, dynamic, deterministic models of pneumococcal transmission in England and Wales to describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in 2010). Key transmission and vaccine parameters were estimated by fitting to carriage data from 2001/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing patterns between ages, and population data. We considered various models to investigate potential reasons for the rapid increase in non-PCV13 (non-vaccine serotype [NVT]) IPD cases since 2014. After searching a large parameter space, 500 parameter sets were identified with a likelihood statistically close to the maximum and these used to predict future cases (median, prediction range from 500 parameter sets). Our findings indicated that the emergence of individual NVTs with higher virulence resulting from ongoing replacement was likely responsible; the NVT increase was predicted to plateau from 2020. Long-term simulation results suggest that changing to a 1+1 schedule would have little overall impact, as the small increase in vaccine-type IPD would be offset by a reduction in NVT IPD. Our results were robust to changes in vaccine assumptions in a sensitivity analysis. Under the base case scenario, a change to a 1+1 schedule in 2018 was predicted to produce 31 (6, 76) additional IPD cases over five years and 83 (-10, 242) additional pneumococcal-CAP cases, with together 8 (-2, 24) additional deaths, none in children under 15 years. Long-term continuation with the 2+1 schedule, or changing to a 1+1, was predicted to sustain current reductions in IPD cases in under-64-year-olds, but cases in 65+-year-olds would continue to increase because of the effects of an aging population. Limitations of our model include difficulty in fitting to past trends in NVT IPD in some age groups and inherent uncertainty about future NVT behaviour, sparse data for defining the mixing matrix in 65+-year-olds, and the methodological challenge of defining uncertainty on predictions. CONCLUSIONS: Our findings suggest that, with the current mature status of the PCV programme in England and Wales, removing one primary dose in the first year of life would have little impact on IPD or pneumococcal CAP cases or associated deaths at any age. A reduction in the number of priming doses would improve programmatic efficiency and facilitate the introduction of new vaccines by reducing the number of coadministered vaccines given at 2 and 4 months of age in the current UK schedule. Our findings should not be applied to other settings with different pneumococcal epidemiology or with immature programmes and poor herd immunity.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Choi YH, Andrews N, Miller E, et al. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study. PLoS Med. 2019. PMID: 31269018. doi:10.1371/journal.pmed.1002845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。